Introduction {#Sec1}
============

Multidetector computed tomography coronary angiography (CTA) has emerged as an important non-invasive imaging modality by providing direct anatomic assessment of coronary artery disease (CAD).[@CR1]-[@CR3] Recently, several studies have shown that, in addition to its value for the diagnosis of CAD, stenosis detection with CTA may also be useful for risk stratification.[@CR4]-[@CR7] Furthermore, besides the assessment of coronary anatomy, left ventricular (LV) function may be evaluated using information derived from the same CTA dataset.[@CR8]-[@CR10] LV function is an established prognostic marker, as has been demonstrated using several imaging modalities including left ventriculography, echocardiography, magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT).[@CR11]-[@CR14] However, no data are currently available concerning the prognostic significance of CTA-derived LV function assessment. The purpose of this study was therefore to determine the prognostic value of CTA-derived LV function analysis and to assess its incremental prognostic value over the detection of significant coronary artery stenosis using CTA.

Methods {#Sec2}
=======

The study group consisted of consecutive patients with suspected or known CAD who were clinically referred for CTA because of chest pain, a positive or inconclusive exercise electrocardiogram (ECG) test, or an elevated risk profile for cardiovascular disease. The study population is part of a large ongoing registry exploring the prognostic value of CTA.[@CR15] For the current analysis, only patients with a CTA examination of diagnostic image quality and with additional LV function data were included. Exclusion criteria for CTA examination were (1) (supra)ventricular arrhythmias, (2) renal failure (glomerular filtration rate \< 30 mL/minutes), (3) known allergy to iodine contrast material, (4) severe claustrophobia, or (5) pregnancy.

CTA Data Acquisition {#Sec3}
--------------------

CTA studies were performed using a 64-row (N = 647) or 320-row (N = 81) multidetector scanner (Aquilion 64, and Aquilion ONE, respectively, Toshiba Medical Systems, Otawara, Japan). One hour prior to the examination, a single dose of oral beta-blocker medication was administered to patients with a heart rate ≥ 65 bpm, unless contraindicated. Based on a pre-defined beta-blocking medication administration protocol, patients with a heart rate between 65 and 75 bpm received 50 mg metoprolol, whereas patients with a heart rate ≥ 75 bpm received 100 mg metoprolol. The total amount of non-ionic contrast media (Iomeron 400; Bracco, Milan, Italy) injected into the antecubital vein was 60-100 mL (depending on body weight and scanner type) at a flow rate of 5.0 or 6.0 mL/second, followed by a saline flush of 25-50 mL. In order to synchronize the arrival of the contrast media, bolus arrival was detected using a real-time bolus tracking technique.[@CR16] All images were acquired during a single inspiratory breath-hold of maximally 12 seconds. For 64-row CTA, a helical-scanning technique was used as previously described.[@CR17],[@CR18] In brief, during the scan, the ECG was registered simultaneously for retrospective gating of the data. A collimation of 64 × .5 mm was used. Additional scan parameters were 400 or 500 ms gantry rotation time depending on cardiac frequency, 120 kV tube voltage, and 300-350 mA (depending on body mass index, (BMI) and thoracic geometry). During 320-row CTA, the ECG was registered simultaneously for prospective triggering of the data. In order to perform LV function analysis, ECG-triggered tube modulation was used, as previously described.[@CR19]

The entire heart was imaged in a single heart beat, attaining maximal tube current during 75% of R--R interval (in patients with stable heart rate \< 60 bpm), during 65-85% of R--R interval (in patients with a heart rate 60-65 bpm), or during 30-80% of R--R interval (in patients with a heart rate \> 65 bpm). Outside the pre-defined interval, tube current was 25% of the maximal tube current. In patients with a heart rate \> 65 bpm images were acquired during multiple heart beats (typically two). A collimation of 320 × .5 mm was used. Additional scan parameters were 350 ms gantry rotation time, 120-135 kV tube voltage, and 400-580 mA (depending on BMI and thoracic geometry). For the 64-row CTA scanner, the estimated average radiation dose for CTA was 17.6 ± 5.6 mSv. For the 320-row CTA scanner, the estimated average radiation dose for single heart beat CTA's using ECG-triggered tube modulation was 10.7 ± 3.6 mSv. In patients, in whom CTA image acquisition was performed during multiple heart beats, average estimated radiation dose was 16.7 ± 6.3 mSv.

Coronary arteries were evaluated using the reconstruction dataset with the least motion artifacts, typically acquired during an end-diastolic phase. To assess LV function and LV volumes, ten series of 2.0-mm slices were reconstructed from the same dataset at every 10% throughout the cardiac cycle, starting at early systole (0% of cardiac cycle) to end-diastole (90% of cardiac cycle).

Data Analysis {#Sec4}
-------------

CTA and LV function reconstructions were transferred to a remote workstation with dedicated analysis software (for 64-row CTA reconstructions: Vitrea 2, Vital Images, Minnetonka, MN, USA; for 320-row CTA reconstructions: Vitrea FX 1.0, Vital Images). The presence of coronary stenosis was assessed by scrolling through axial images, combined with visual assessment of curved multiplanar reconstructions in ≥ 2 orthogonal planes. CTA examinations were evaluated on a patient basis for the presence of a significant stenosis (≥ 50% luminal narrowing) by two experienced observers. Discrepancies in interpretation were resolved by consensus.

For the purpose of LV function analysis, appropriate phases for LV end-systolic volume (LVESV) and LV end-diastolic volume (LVEDV) were acquired, by selecting the smallest and largest cross-sectional LV cavity areas, respectively. Upper limit of the LV was determined at the basal level of the mitral valve and the start of the LV outflow tract, as previously described.[@CR20] Endocardial borders were outlined using a semi-automated method from the base to the apex on the short-axis cine images by an independent observer. Papillary muscles were excluded from the ventricular cavity. The LVEDV and LVESV volumes were calculated and the LVEF was derived by subtracting the LVESV from the LVEDV and dividing the result by the LVEDV.[@CR9] Observers for LV function analysis were blinded to CTA data.

End-Points {#Sec5}
----------

Patient follow-up data were gathered by a single observer, blinded to the baseline CTA results, using clinical visits and/or standardized telephone interviews. A composite end-point was constructed using the following events: all-cause mortality, non-fatal myocardial infarction, and unstable angina pectoris requiring hospitalization. Non-fatal infarction was defined based on criteria of typical chest pain, elevated cardiac enzyme levels, and typical changes on the ECG.[@CR21] Unstable angina was defined according to the European Society of Cardiology guidelines as acute chest pain with or without the presence of ECG abnormalities, and negative cardiac enzyme levels.[@CR22]

Statistical Analysis {#Sec6}
--------------------

Statistical analysis was performed using SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA). Quantitative data were expressed as mean ± SD. Categorical variables were described as numbers and percentages. Cox regression analysis was used to determine the prognostic value of the presence of significant stenosis and LV function parameters on CTA. First, univariate analysis of baseline characteristics, the presence of significant stenosis, and LV function parameters was performed using a composite end-point of all-cause mortality, non-fatal infarction, and unstable angina. For each variable, a hazard ratio (HR) with a 95% confidence interval (CI) was calculated. Increased LVEDV and LVESV were defined as LVEDV \> 215 mL, LVESV \> 90 mL and reduced LVEF was defined as LVEF \< 49%, as described previously.[@CR23] These values were determined using the 95% CI boundaries for 3D LV dimensions and function as determined by CTA.[@CR23] After univariate analysis, several multivariate models were created to correct LV function parameters for clinical risk factors and the presence of significant stenosis on CTA. In case variables showed strong interrelation (Pearson's correlation coefficient \> .8), variables were excluded from the same multivariate model. Finally, the incremental value of LV function variables over clinical risk factors (age, gender, smoking, and known CAD) and the presence of significant stenosis on CTA were assessed by calculating the global χ^2^ values. A *P*-value \< .05 was considered statistically significant.

Results {#Sec7}
=======

From the registry, additional LV function measurements (derived from CTA) were available in 813 patients. In 29 patients (3.6%) the CTA examination was of non-diagnostic image quality and these patients were excluded from the study. Furthermore, a total of 56 patients (6.9%) were lost to follow-up. As a result, the patient group consisted of 728 individuals. The main clinical characteristics of the population are listed in Table [1](#Tab1){ref-type="table"}. In summary, 55% were male and the mean age was 55 ± 12 years.Table 1Patient characteristicsTotal: N = 728Gender (male/female)400/328Age (years)55 ± 12Reason for referral Typical chest pain83 (12%) Atypical chest pain189 (26%) Non-anginal chest pain132 (18%) Elevated risk profile213 (29%) Positive or inconclusive exercise ECG111 (15%)Clinical risk factors Diabetes222 (31%) Hypercholesterolemia\*261 (36%) Hypertension^†^317 (44%) Family history of coronary artery disease^‡^309 (42%) Smoking137 (19%) Obesity (BMI ≥ 30 kg/m^2^)143 (20%) Known CAD96 (13%)\*Serum total cholesterol ≥ 230 mg/dL and/or serum triglycerides ≥ 200 mg/dL or treatment with lipid lowering drugs.^†^Defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medication.^‡^Defined as presence of coronary artery disease in first degree family members at \< 55 years in men and \< 65 years in women.*BMI*, Body mass index; *CAD*, coronary artery disease.

Baseline CTA and LV Function {#Sec8}
----------------------------

In the study population of 728 patients, a significant stenosis (luminal narrowing ≥ 50%) was identified on CTA in 221 patients (30%). When evaluating LV volumes, an average LVEDV of 138 ± 38 mL was observed. For LVESV an average value of 52 ± 29 mL was observed. As a result, average LVEF was 64 ± 10%. Increased LVEDV (\> 215 mL) and LVESV (\> 90 mL) were present in 31 patients (4.3%) and 50 patients (6.9%), respectively. A reduced LVEF (\< 49%) was present in 43 patients (7.3%).

Follow-up {#Sec9}
---------

The median follow-up period was 765 days (25-75th percentile: 493-978); an event occurred in 45 patients (6.2%). All-cause death was reported in 23 patients (3.2%), non-fatal myocardial infarction occurred in 7 patients (1.0%), and 15 patients (2.0%) were admitted to the hospital due to unstable angina.

Survival Analysis {#Sec10}
-----------------

Univariate analysis of clinical risk factors, significant stenosis on CTA, and LV function analysis parameters is depicted in Table [2](#Tab2){ref-type="table"}. Of the clinical risk factors, age, smoking, and known CAD were significant predictors of events. Also, the presence of a significant stenosis on CTA was identified as a significant predictor of events. Regarding LV function, all three parameters (LVEDV, LVESV, and LVEF) were significant univariate predictors when assessed as continuous variables and categorical variables, using predefined cutoff values.Table 2Univariate predictors of eventsHR (95% CI)*P*-valueBaseline clinical characteristic Age1.04 (1.01--1.07).005 Male gender1.36 (.75--2.49).315 Diabetes1.03 (.55--1.93).939 Hypercholesterolemia\*.73 (.38--1.39).333 Hypertension^†^.89 (.53--1.73).958 Family history of coronary artery disease^‡^.61 (.32--1.15).125 Smoking2.31 (1.25--4.25).007 Obesity (BMI ≥ 30 kg/m^2^).55 (.22--1.39).205 Known CAD2.74 (1.46--5.13).002CTA Significant stenosis3.52 (1.59--7.83).002LV function (continuous) LVEDV (per 10 mL increase)1.07 (1.00--1.14).048 LVESV (per 10 mL increase)1.10 (1.03--1.18).006 LVEF (per % increase).97 (.94--.99).006LV function (categorical) LVEDV \> 215 mL2.89 (1.22--6.86).016 LVESV \> 90 mL3.95 (1.99--7.84)\<.001 LVEF \< 49%3.82 (1.93--7.57)\<.001\*Serum total cholesterol ≥ 230 mg/dL and/or serum triglycerides ≥ 200 mg/dL or treatment with lipid lowering drugs.^†^Defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medication.^‡^Defined as presence of coronary artery disease in first degree family members at \< 55 years in men and \< 65 years in women.*BMI*, Body mass index; *CAD*, coronary artery disease; *CI*, confidence interval; *CTA*, computed tomography coronary angiography; *HR*, hazard ratio; *LVEDV*, left ventricular end-diastolic volume; *LVEF*, left ventricular ejection fraction; *LVESV*, left ventricular end-systolic volume.

Multivariate models were created correcting for clinical risk factors (age, gender, smoking, and known CAD) and significant stenosis on CTA. The prognostic values of LV volumes and LVEF are shown in Table [3](#Tab3){ref-type="table"}. A total of six models were created. In the first three models, LVEDV, LVESV and LVEF were assessed as continuous variables, whereas in the last three models the predictive value of LV function was determined using the pre-defined cutoff values to indicate reduced LV function. Although none of the continuous LV function variables remained independent predictors of events, using the pre-defined cutoff values as markers for reduced LV function, increased LVESV and reduced LVEF provided additional prognostic information over clinical risk factors and significant stenosis on CTA. Figure [1](#Fig1){ref-type="fig"} illustrates the incremental prognostic value, depicted by χ^2^ value, of LVESV \> 90 mL over age, gender, smoking, known CAD, and significant stenosis on CTA (*P* \< .05). Similarly, Figure [2](#Fig2){ref-type="fig"} shows that LVEF \< 49% has incremental value (*P* \< .05), and thus enhanced risk stratification beyond the detection of significant stenosis using CTA.Table 3Multivariate models for the prediction of eventsHR (95% CI)*P*-valueLV function (continuous) LVEDV\* (per 10 ml increase)1.05 (.99--1.13).123 LVESV\* (per 10 ml increase)1.06 (.98--1.15).119 LVEF\* (per % increase).98 (.96--1.01).177LV function (categorical) LVEDV \> 215 mL\*1.98 (.79--4.95).143 LVESV \> 90 mL\*3.11 (1.45--6.67).004 LVEF \< 49%\*2.61 (1.22--5.60).014\*Corrected for baseline clinical variables (age, gender, smoking, known CAD) and significant stenosis on CTA.*CAD*, Coronary artery disease; *CI*, confidence interval; *HR*, hazard ratio; *LVEDV*, left ventricular end-diastolic volume; *LVEF*, left ventricular ejection fraction; *LVESV*, left ventricular end-systolic volume.Figure 1Bar graph illustrating the incremental prognostic value (depicted by χ^2^ values on the *y*-axis) of LVESV \> 90 mL over age, gender, smoking, known CAD, and significant stenosis. The presence of significant stenosis on CTA has a significant incremental prognostic value over age, gender, smoking, and known CAD (asterisk). A further incremental prognostic value over clinical risk factors and significant stenosis on CTA is observed with the addition of LVESV \> 90 mL (\#). *CAD*, Coronary artery disease; *LVESV*, left ventricular end-systolic volumeFigure 2Bar graph illustrating the incremental prognostic value (depicted by χ^2^ values on the *y*-axis) of LVEF \< 49% over age, gender, smoking, known CAD, and significant stenosis on CTA. The presence of significant stenosis on CTA has a significant incremental prognostic value over age, gender, smoking, and known CAD (asterisk). A further incremental prognostic value over clinical risk factors and significant stenosis on CTA is observed with the addition of LVEF \< 49% (\#). *CAD*, Coronary artery disease; *LVEF*, left ventricular ejection fraction

Discussion {#Sec11}
==========

The main finding of this study is that CTA-derived LV function may provide important prognostic information beyond the detection of significant stenosis on CTA.

LV volumes and LVEF are used extensively as clinical markers of cardiac function. In patients with known CAD, LV function analysis provides important information for risk assessment and further management.[@CR11],[@CR24] Post-myocardial infarction patients with a normal LVEF have a relatively good prognosis, whereas the risk of future events has been shown to increase with deteriorating LVEF.[@CR25] LV function analysis may also be useful in patients with suspected CAD. Using 2D echocardiography in 2,948 patients without prevalent CAD, Devereux et al[@CR12] showed that LVEF \< 40% was a strong predictor of cardiovascular death (RR 6.9, CI 3.0-15.9, *P* \< .001) and all-cause mortality (RR 4.8, CI 2.8-8.1, *P* \< .001), independent of clinical risk factors. In a study by Sharir et al,[@CR14] evaluating 1,680 patients referred for gated SPECT, LVEF \< 45% and ESV \> 70 mL were identified as optimal thresholds to accurately stratify patients into high-risk and low-risk groups. Importantly, patients with a normal LVEF or LVESV had a substantially lower annual mortality rate (regardless of the degree of perfusion abnormalities on SPECT) than patients with reduced LVEF or increased LVESV. In this study, the prognostic value of LV function measurements on CTA was evaluated. LV volumes and LVEF provided prognostic information independent of baseline clinical variables. These findings illustrate that measurements of LV function (and volumes) from CTA acquisitions can be beneficial in defining patient risk and if available should be incorporated into the clinical report.

Importantly, patients undergoing CTA are primarily referred for assessment of CAD. As this anatomic information has been established to provide prognostic information,[@CR4]-[@CR6] an important objective of this study was to determine the additional value of LV function analysis beyond the detection of significant CAD. Limited information is available regarding the additional prognostic value of LV function over the non-invasive angiographic assessment of CAD using CTA. In a recent study by Min et al,[@CR26] evaluating 5,330 consecutive patients without known CAD with a mean follow-up of 2.3 ± .6 years, the addition of LV function measured by CTA significantly increased risk correlation for death. Annualized mortality rates in patients with significant CAD and LVEF ≤ 50% were significantly higher (3.79%) than in patients with significant CAD and LVEF \> 50% (1.76%). Furthermore, Chow et al[@CR27] recently determined the incremental prognostic value of LV function measured with CTA in 2,076 consecutive patients with a mean follow-up of 16 ± 8 months. It was shown that LVEF had incremental prognostic value over CAD severity (HR 1.47, 95% CI 1.17-1.86). These data indicate that LV function is an important predictor of survival with incremental value to CTA. In line with these results, this study suggests that, although the assessment of significant CAD on CTA is a powerful predictor, LV function parameters provide independent incremental value in predicting adverse events. Thus, the addition of LV function analysis to CTA may further improve risk stratification of patients with known of suspected CAD referred for stenosis detection.

Limitations {#Sec12}
-----------

Several limitations of this study merit consideration. First, 6.9% of patients were lost to follow-up. Second, regional wall motion abnormalities were not assessed in this study. Third, this study is limited by a relatively small patient number. Fourth, CTA is inherently associated with radiation exposure.[@CR28] As a result, prospective ECG triggering was recently introduced for the purpose of radiation reduction.[@CR29],[@CR30] This technique allows image acquisition during a small portion of the cardiac cycle which significantly reduces the radiation exposure. However, as a result data are no longer acquired throughout the entire cardiac cycle, thereby eliminating the possibility of simultaneous LV function analysis from the same dataset. Although LV function may still be assessed, it has become at the expense of increased radiation exposure, also when using ECG-triggered tube current modulation. Therefore, the necessity of LV function analysis using CTA should be carefully weighed against the increase in radiation burden. Importantly, LV function analysis may also be performed using radiation-free modalities, such as echocardiography or MRI. Accordingly, although in this study LV function was derived from CTA, LV function analysis may enhance risk stratification beyond the presence of significant stenosis on CTA regardless of the modality used to derive this information. Additional studies are warranted to gain better understanding of the integration of angiographic and LV function data to refine risk stratification.
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